Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Rac1 palmitoylation is required for cardiac stress adaptation and regulation of protein kinase A signaling
James P. Teuber, Rachel E. Scissors, Arasakumar Subramani, Nageswara Madamanchi, Matthew J. Brody
James P. Teuber, Rachel E. Scissors, Arasakumar Subramani, Nageswara Madamanchi, Matthew J. Brody
View: Text | PDF
Research Article Cardiology Cell biology

Rac1 palmitoylation is required for cardiac stress adaptation and regulation of protein kinase A signaling

  • Text
  • PDF
Abstract

Cardiac hypertrophy is a common adaptation to cardiovascular stress and often a prelude to heart failure. We examined how S-palmitoylation of the small GTPase, Ras-related C3 botulinum toxin substrate 1 (Rac1), impacts cardiomyocyte stress signaling. Mutation of the Cys-178 palmitoylation site impaired activation of Rac1 when overexpressed in cardiomyocytes. Cardiomyocyte-specific Rac1 conditional knockin (Rac1cKI) mice expressing a Rac1C178S mutant protein exhibited normal cardiac structure and function but developed more severe cardiac hypertrophy in response to angiotensin II (AngII) infusion, cardiomyocyte-specific overexpression of AngII type 1 receptor (AT1R), and cardiac pressure overload. Moreover, pressure overload and AT1R overexpression evoked cardiac failure phenotypes in Rac1cKI mice not observed in controls. Mechanistically, Rac1cKI hearts and cardiomyocytes genetically resistant to Rac1 S-palmitoylation had a profound increase in protein kinase A (PKA) substrate phosphorylation in response to acute β-adrenergic stimulation, as did Rac1cKI hearts subjected to chronic AngII treatment, AT1R overexpression, or pressure overload that correlates with more advanced heart failure phenotypes. This was not associated with increased PKA enzymatic activity, suggesting potential deficits in phosphatase activity at PKA-regulated phospho-sites. Taken together, this study suggests Rac1 S-palmitoylation dampens adrenergic drive and PKA-dependent modulation of the phospho-proteome in response to cardiovascular stress, revealing essential functions for S-acylated Rac1 in cardiac adaptation.

Authors

James P. Teuber, Rachel E. Scissors, Arasakumar Subramani, Nageswara Madamanchi, Matthew J. Brody

×

Figure 9

Working model of Rac1 Cys-178 palmitoylation in the regulation of cardiac remodeling and adrenergic signaling.

Options: View larger image (or click on image) Download as PowerPoint
Working model of Rac1 Cys-178 palmitoylation in the regulation of cardia...
Circulating levels of norepinephrine and angiotensin II are elevated during chronic hypertrophic stress. Activation of the β1AR elicits Gs-dependent activation of adenylyl cyclase, leading to cAMP production and protein kinase A (PKA) activation. Active PKA phosphorylates substrates critical for excitation-contraction coupling. AT1R activation leads to Rac1 activation and promotes Rac1 S-palmitoylation cycling. S-palmitoylated Rac1 is required to evoke dephosphorylation of PKA substrates and dampen excessive adrenergic signaling that promotes cardiac maladaptation, likely through Pak1-dependent activation of PP2A. Upon loss of Rac1 palmitoylation cycling at Cys-178 (as observed in Rac1cKI hearts), PP2A-mediated antagonism of PKA substrate activity is not properly regulated, resulting in hyperphosphorylation of PKA substrates that chronically promotes cardiac decompensation, systolic dysfunction, and adverse hypertrophic remodeling. AC, adenylyl cyclase; AngII, angiotensin II; AT1R, angiotensin II receptor type I; β1AR, β1 adrenergic receptor; LTCC, L-type calcium channel; MyBPC3, myosin binding protein C3; NE, norepinephrine; Pak1, p21-activated kinase-1; PKA, protein kinase A; PLN, phospholamban; PP2A, protein phosphatase 2A; SERCA, sarco-endoplasmic reticulum calcium ATPase; TnI, troponin I; TnT, troponin T.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts